Drug intelligence / Profile preview

ABT-501

Development stage: Preclinical
Lead developer: Anbogen Therapeutics
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides

Overview

ABT-501 is a peptide drug conjugate developed by AnBogen Therapeutics. It acts as a modulator of the gonadotropin-releasing hormone receptor (GnRHR). The drug is being investigated primarily for oncology and endocrine-related indications, with its main therapeutic areas including neoplasms (notably ovarian cancer and triple negative breast cancer), endocrinology and metabolic diseases, as well as skin and musculoskeletal diseases. As of the latest update in March 2025, its highest development status globally is preclinical[1][3].

Targets

GnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on ABT-501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABT-501.

Explore the full profile